An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Latest Information Update: 13 Feb 2024
At a glance
- Drugs Rozanolixizumab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Registrational
- Acronyms myOpportunITy3
- Sponsors UCB Biopharma
- 02 Feb 2024 Status changed from completed to discontinued because of a strategic business decision but not for any safety concern.
- 25 May 2023 This trial has been completed in Poland (End Date: 23 Dec 2023), according to European Clinical Trials database record.
- 19 Jan 2023 This trial has been discontinued in Hungary (End Date: 14 April 2022) according to European Clinical Trials Database record.